ClinicalTrials.gg

Program

HMI-115

A development code. Also written as “HMI-115-120mg-Q4W”, “HMI-115-240mg-Q4W” and “HMI-115, 240mg-Q2W”.

Its studies are mostly in Endometriosis · Alopecia, led by Hope Medicine (Nanjing).

Furthest: phase 3, since Dec 29, 20254 company-led studies, 1 open or runningNext primary completion: Mar 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hope Medicine (Nanjing)41 open or runningphase 3since Dec 29, 2025Oct 9, 2021Mar 1, 2028phase 3 · NCT07318688

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 9, 2021First study: phase 2 study in EndometriosisFirst studyNCT05101317 · 142 enrolled · United States, China, Poland
  2. Mar 30, 2022Phase 1 study in AlopeciaNCT05324293 · 16 enrolled · Australia
  3. Oct 16, 2023Phase 2 study in AlopeciaNCT06118866 · 192 enrolled · China
  4. Dec 29, 2025Phase 3 study in EndometriosisPhase 3 reachedNCT07318688 · 540 planned · China

Ahead

  1. Mar 1, 2028Primary completion: phase 3 study in EndometriosisNCT07318688

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07318688Endometriosis · China3RecruitingMar 1, 2028540
NCT06118866Alopecia · China2CompletedAug 26, 2024192
NCT05324293Alopecia · Australia1CompletedSep 11, 202316
NCT05101317Endometriosis · United States, China, Poland2CompletedSep 26, 2024142

How it is read

Names in the registry

  • “HMI-115”, 3 entries
  • “HMI-115-120mg-Q4W”, 1 entry
  • “HMI-115-240mg-Q4W”, 1 entry
  • “HMI-115, 240mg-Q2W”, 1 entry

Codes read as this program: HMI115.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.